Lexicon Pharmaceuticals Inc (LXRX) News & EventsLXRXLexicon Pharmaceuticals Inc

Lexicon Announces Heart Failure Drug Study Results

Lexicon announced results from a post hoc analysis of the Phase 3 SOLOIST-WHF trial evaluating the efficacy and safety of sotagliflozin across the spectrum of baseline systolic blood pressure in patients recently hospitalized for worsening heart failure. The data, which were presented at ESC Congress in Munich, Germany and simultaneously published in JACC: Heart Failure, demonstrated that the results of sotagliflozin treatment were maintained regardless of baseline systolic blood pressure. Among patients with baseline systolic blood pressure as low as 100 mmHg, treatment with sotagliflozin was associated with a reduction in cardiovascular death and heart failure-related events, without an increase in hypotension or acute kidney injury. Among patients with a baseline SBP less than110 mmHg, those randomized to sotagliflozin experienced a reduction in total occurrences of cardiovascular deaths and HF-related events. These data suggest efficacy of sotagliflozin in even the lowest SBP stratum. There was no difference in the incidence of adverse events of hypotension between treatment groups or AKI. Additionally, patients with a baseline SBP greater than or equal to 110 mmHg also experienced a reduction in total occurrences of cardiovascular deaths and HF-related events.

Lexicon Earns $10M Milestone Payment from Novo Nordisk

Lexicon (LXRX) announced that it has earned a third $10M milestone payment in 2026 from Novo Nordisk (NVO) following the achievement of a patient dosing milestone in the ongoing Phase 1 clinical development program for LX9851. LX9851 is being advanced by Novo Nordisk under the companies' exclusive worldwide license agreement signed in 2025. Under the terms of the agreement, Novo Nordisk obtained an exclusive, worldwide license to develop, manufacture and commercialize LX9851 in all indications. With the achievement of this milestone, Lexicon has now earned $75M of the $1B in potential upfront, development, regulatory and commercial milestone payments available under its collaboration with Novo Nordisk. In addition, Lexicon is entitled to receive tiered royalties on future net sales of LX9851.

Selling Stockholders Plan to Sell 1.26M Shares of Common Stock

This filing relates to the offer and sale from time to time by the selling stockholders of up to 1.26M shares of common stock. The company is not selling any shares under this prospectus and will not receive any of the proceeds from the sale of shares by the selling stockholders.